These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

583 related articles for article (PubMed ID: 20570401)

  • 1. Relations between brain tissue loss, CSF biomarkers, and the ApoE genetic profile: a longitudinal MRI study.
    Tosun D; Schuff N; Truran-Sacrey D; Shaw LM; Trojanowski JQ; Aisen P; Peterson R; Weiner MW;
    Neurobiol Aging; 2010 Aug; 31(8):1340-54. PubMed ID: 20570401
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Relationship between CSF biomarkers of Alzheimer's disease and rates of regional cortical thinning in ADNI data.
    Tosun D; Schuff N; Shaw LM; Trojanowski JQ; Weiner MW;
    J Alzheimers Dis; 2011; 26 Suppl 3(0 3):77-90. PubMed ID: 21971452
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apolipoprotein E epsilon4 does not modulate amyloid-β-associated neurodegeneration in preclinical Alzheimer disease.
    Desikan RS; McEvoy LK; Holland D; Thompson WK; Brewer JB; Aisen PS; Andreassen OA; Hyman BT; Sperling RA; Dale AM;
    AJNR Am J Neuroradiol; 2013 Mar; 34(3):505-10. PubMed ID: 22976236
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Apolipoprotein E genotype and the diagnostic accuracy of cerebrospinal fluid biomarkers for Alzheimer disease.
    Lautner R; Palmqvist S; Mattsson N; Andreasson U; Wallin A; Pålsson E; Jakobsson J; Herukka SK; Owenius R; Olsson B; Hampel H; Rujescu D; Ewers M; Landén M; Minthon L; Blennow K; Zetterberg H; Hansson O;
    JAMA Psychiatry; 2014 Oct; 71(10):1183-91. PubMed ID: 25162367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effect of apolipoprotein E on biomarkers of amyloid load and neuronal pathology in Alzheimer disease.
    Vemuri P; Wiste HJ; Weigand SD; Knopman DS; Shaw LM; Trojanowski JQ; Aisen PS; Weiner M; Petersen RC; Jack CR;
    Ann Neurol; 2010 Mar; 67(3):308-16. PubMed ID: 20373342
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Magnetic resonance imaging improves cerebrospinal fluid biomarkers in the early detection of Alzheimer's disease.
    Brys M; Glodzik L; Mosconi L; Switalski R; De Santi S; Pirraglia E; Rich K; Kim BC; Mehta P; Zinkowski R; Pratico D; Wallin A; Zetterberg H; Tsui WH; Rusinek H; Blennow K; de Leon MJ
    J Alzheimers Dis; 2009; 16(2):351-62. PubMed ID: 19221425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Brain ventricular volume and cerebrospinal fluid biomarkers of Alzheimer's disease.
    Ott BR; Cohen RA; Gongvatana A; Okonkwo OC; Johanson CE; Stopa EG; Donahue JE; Silverberg GD;
    J Alzheimers Dis; 2010; 20(2):647-57. PubMed ID: 20182051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Serial MRI and CSF biomarkers in normal aging, MCI, and AD.
    Vemuri P; Wiste HJ; Weigand SD; Knopman DS; Trojanowski JQ; Shaw LM; Bernstein MA; Aisen PS; Weiner M; Petersen RC; Jack CR;
    Neurology; 2010 Jul; 75(2):143-51. PubMed ID: 20625167
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects.
    Shaw LM; Vanderstichele H; Knapik-Czajka M; Clark CM; Aisen PS; Petersen RC; Blennow K; Soares H; Simon A; Lewczuk P; Dean R; Siemers E; Potter W; Lee VM; Trojanowski JQ;
    Ann Neurol; 2009 Apr; 65(4):403-13. PubMed ID: 19296504
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association between Cerebrospinal Fluid Biomarkers for Alzheimer's Disease, APOE Genotypes and Auditory Verbal Learning Task in Subjective Cognitive Decline, Mild Cognitive Impairment, and Alzheimer's Disease.
    Mandecka M; Budziszewska M; Barczak A; Pepłońska B; Chodakowska-Żebrowska M; Filipek-Gliszczyńska A; Nesteruk M; Styczyńska M; Barcikowska M; Gabryelewicz T
    J Alzheimers Dis; 2016 Jul; 54(1):157-68. PubMed ID: 27472875
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cognition, brain atrophy, and cerebrospinal fluid biomarkers changes from preclinical to dementia stage of Alzheimer's disease and the influence of apolipoprotein e.
    Susanto TA; Pua EP; Zhou J;
    J Alzheimers Dis; 2015; 45(1):253-68. PubMed ID: 25524955
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotype.
    Blom ES; Giedraitis V; Zetterberg H; Fukumoto H; Blennow K; Hyman BT; Irizarry MC; Wahlund LO; Lannfelt L; Ingelsson M
    Dement Geriatr Cogn Disord; 2009; 27(5):458-64. PubMed ID: 19420940
    [TBL] [Abstract][Full Text] [Related]  

  • 13. APOE ε4 moderates abnormal CSF-abeta-42 levels, while neurocognitive impairment is associated with abnormal CSF tau levels in HIV+ individuals - a cross-sectional observational study.
    Cysique LA; Hewitt T; Croitoru-Lamoury J; Taddei K; Martins RN; Chew CS; Davies NN; Price P; Brew BJ
    BMC Neurol; 2015 Apr; 15():51. PubMed ID: 25880550
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CSF biomarkers in prediction of cerebral and clinical change in mild cognitive impairment and Alzheimer's disease.
    Fjell AM; Walhovd KB; Fennema-Notestine C; McEvoy LK; Hagler DJ; Holland D; Brewer JB; Dale AM;
    J Neurosci; 2010 Feb; 30(6):2088-101. PubMed ID: 20147537
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF Apo-E levels associate with cognitive decline and MRI changes.
    Toledo JB; Da X; Weiner MW; Wolk DA; Xie SX; Arnold SE; Davatzikos C; Shaw LM; Trojanowski JQ;
    Acta Neuropathol; 2014 May; 127(5):621-32. PubMed ID: 24385135
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Reciprocal Predictive Relationships between Amyloid and Tau Biomarkers in Alzheimer's Disease Progression: An Empirical Model.
    Krance SH; Cogo-Moreira H; Rabin JS; Black SE; Swardfager W;
    J Neurosci; 2019 Sep; 39(37):7428-7437. PubMed ID: 31350262
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Longitudinal structural cerebral changes related to core CSF biomarkers in preclinical Alzheimer's disease: A study of two independent datasets.
    Falcon C; Tucholka A; Monté-Rubio GC; Cacciaglia R; Operto G; Rami L; Gispert JD; Molinuevo JL;
    Neuroimage Clin; 2018; 19():190-201. PubMed ID: 30023169
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Multiple Effect of APOE Genotype on Clinical and Neuroimaging Biomarkers Across Alzheimer's Disease Spectrum.
    Liu Y; Tan L; Wang HF; Liu Y; Hao XK; Tan CC; Jiang T; Liu B; Zhang DQ; Yu JT;
    Mol Neurobiol; 2016 Sep; 53(7):4539-47. PubMed ID: 26298664
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MRI and CSF biomarkers in normal, MCI, and AD subjects: predicting future clinical change.
    Vemuri P; Wiste HJ; Weigand SD; Shaw LM; Trojanowski JQ; Weiner MW; Knopman DS; Petersen RC; Jack CR;
    Neurology; 2009 Jul; 73(4):294-301. PubMed ID: 19636049
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Progression to dementia in memory clinic patients with mild cognitive impairment and normal β-amyloid.
    Rosenberg A; Solomon A; Jelic V; Hagman G; Bogdanovic N; Kivipelto M
    Alzheimers Res Ther; 2019 Dec; 11(1):99. PubMed ID: 31805990
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.